Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) J B A G Haanen et al.   ANNALS OF ONCOLOGY

It is finally time for adjuvant therapy in melanoma

(2018) S. Napolitano et al.   CANCER TREATMENT REVIEWS

Sarcoid-like reactions in patients receiving modern melanoma treatment

(2018) Florentia Dimitriou et al.   MELANOMA RESEARCH

Safety of combining radiotherapy with immune-checkpoint inhibition

(2018) William L. Hwang et al.   Nature Reviews Clinical Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

(2018) Fei Tang et al.   Cell and Bioscience

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

(2018) Yiting Wang et al.   Frontiers in Pharmacology

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

(2018) Shifaa Abdin et al.   Cancers

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

(2018) Tara C. Mitchell et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

(2018) Marcin Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CTLA-4 therapy for malignant mesothelioma

(2017) Alice Guazzelli et al.   Immunotherapy

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Shallow and Deep Learning Methods on Classifying the Regional Pattern of Diffuse Lung Disease

(2017) Guk Bae Kim et al.   JOURNAL OF DIGITAL IMAGING

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know

(2017) Marta Braschi-Amirfarzan et al.   KOREAN JOURNAL OF RADIOLOGY

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

(2017) Julie R Brahmer et al.   LANCET ONCOLOGY

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma

(2017) Chunyan Hao et al.   MEDICINE

The benefits of immunotherapy combinations

(2017) Charles Schmidt   NATURE

PD1 signal transduction pathways in T cells

(2017) Hugo Arasanz et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Multisource Transfer Learning With Convolutional Neural Networks for Lung Pattern Analysis

(2017) Stergios Christodoulidis et al.   IEEE Journal of Biomedical and Health Informatics

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

(2017) Yohei Masugi et al.   Cancer Immunology Research

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

(2016) M. Nishino et al.   CLINICAL CANCER RESEARCH

Lung Pattern Classification for Interstitial Lung Diseases Using a Deep Convolutional Neural Network

(2016) Marios Anthimopoulos et al.   IEEE TRANSACTIONS ON MEDICAL IMAGING

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors

(2016) Belal Firwana et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs

(2015) Takeshi Johkoh et al.   EUROPEAN JOURNAL OF RADIOLOGY

Automated Classification of Usual Interstitial Pneumonia Using Regional Volumetric Texture Analysis in High-Resolution Computed Tomography

(2015) Adrien Depeursinge et al.   INVESTIGATIVE RADIOLOGY

Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer

(2015) Matthew Howell et al.   LUNG CANCER

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

(2015) Mizuki Nishino et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

(2015) Jennifer J. Kwak et al.   RADIOGRAPHICS

PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity

(2015) Tong Seng Lim et al.   OncoImmunology

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

(2014) Vassiliki A. Boussiotis et al.   CANCER JOURNAL

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Mechanism of Action of Immunotherapy

(2014) Mary L. Disis   SEMINARS IN ONCOLOGY

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

(2013) William D. Travis et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma

(2013) Igor Z. Barjaktarevic et al.   CHEST

Treg and CTLA-4: Two intertwining pathways to immune tolerance

(2013) Lucy S.K. Walker   JOURNAL OF AUTOIMMUNITY

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab

(2012) Grégoire Berthod et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity

(2010) N. Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

(2010) Antoni Ribas   SEMINARS IN ONCOLOGY

PD-1 on dendritic cells impedes innate immunity against bacterial infection

(2009) S. Yao et al.   BLOOD

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy

(2009) Joseph R. Podojil et al.   IMMUNOLOGICAL REVIEWS

Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages

(2008) Hae-Yun Cho et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms